Compare Synchrony Financial (SYF) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Synchrony Financial vs BIO-TECHNE Corp — how do they compare? Synchrony Financial trades at $71.7 (market cap $24.69B), while BIO-TECHNE Corp trades at $71.63 (market cap $11.16B). The key difference: Synchrony Financial is far larger — about 2.2× BIO-TECHNE Corp's market cap, and Synchrony Financial pays the higher dividend (1.63%). Which is the better fit depends on your goals.
| SYF | TECH | |
|---|---|---|
Market Cap | $24.69B | $11.16B |
Sector | Financials | Health |
52-Week High | $88.47 | $72.12 |
52-Week Low | $63.78 | $43.31 |
Dividend Yield | 1.63% | 0.45% |
Enterprise Value | — | $11.24B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
